Background: Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib and trastuzumab significantly improved rates of pathological complete response compared with either drug alone. Here, we report data for the prespecified secondary endpoints of event-free and ...

2014年8月14日 · Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib and trastuzumab significantly improved rates of pathological complete response compared with either drug alone.

2012年2月18日 · Background: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy.

Long-term (6.7 years) follow-up analysis of HERACLES-A supports using of trastuzumab and lapatinib as treatment reference for KRAS wild-type, chemorefractory HER2-positive mCRC. In this subset of patients, prolongation of survival is accompanied by CNS recurrences that will require diagnostic and th …

2012年2月18日 · In the NeoAdjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) study, we assessed lapatinib, trastuzumab, and their combination as neoadjuvant therapy for women with HER2-positive early breast cancer.

2024年11月2日 · We found that trastuzumab combined with lapatinib therapy significantly improved OS and DFS/EFS, compared to standard trastuzumab therapy alone while lapatinib plus chemotherapy had a lower efficacy in OS, PFS, and DFS/EFS, compared to standard trastuzumab therapy.

2014年3月4日 · In this phase II trial we evaluated the efficacy and toxicity of trastuzumab and lapatinib when added to standard NAC (that is, epirubicin, cyclophosphamide, and docetaxel) for patients with HER2-positive early stage or inflammatory breast cancer.

2020年11月17日 · Synergistic interactions between trastuzumab and the oral HER1/HER2-targeted tyrosine kinase inhibitor lapatinib have been observed in HER2-overexpressing cell lines 15, 16 and in HER2+ tumor...

2010年3月1日 · Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastuzumab significantly improved PFS and CBR versus lapatinib alone, thus offering a chemotherapy-free option with an acceptable safety profile to …

2016年4月1日 · Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain.